Fulcrum Therapeutics, Inc. announced the pricing of its public offering of 11,851,853 shares of common stock at $13.50 per share, with expected gross proceeds of $175.0 million, for general corporate purposes. The offering is managed by J.P. Morgan, Leerink Partners, and Cantor, and is expected to close on December 11, 2025. The securities are being offered under an effective shelf registration statement filed with the SEC. Copies of the prospectus supplement can be obtained from the managing book-runners. Fulcrum is focused on developing small molecules for rare diseases, with its lead program targeting sickle cell disease.

This press release contains forward-looking statements regarding the public offering and use of proceeds. Risks and uncertainties could cause actual results to differ, including fluctuations in stock price and market conditions. Fulcrum’s ability to complete the offering on anticipated terms is not guaranteed. Information is current as of the release date, and Fulcrum has no obligation to update unless required by law. For more information, contact Kevin Gardner at LifeSci Advisors, LLC.

Read more at GlobeNewswire: Fulcrum Therapeutics Announces Pricing of Upsized $175.0